Protyon

Protyon is a Dutch healthtech company and a spin-out from the University of Groningen and the University Medical Centre Groningen. It has developed predictive software that utilizes computational molecular modeling and artificial intelligence to support clinical decision-making in cancer therapy. By creating 3D digital models based on the genetic code of cancer mutations, the company's platform predicts the effectiveness of targeted therapies by analyzing how small molecules interact with drug targets and associated mutations. This approach is designed to be distinct from traditional chemical research, offering high predictive power for identifying optimal treatment alternatives, particularly for patients with protein-linked mutations.

The technology is primarily applied to assist clinicians in choosing the most effective personalized treatment plans, aiming to enhance patient quality of life and reduce healthcare costs by avoiding ineffective medications. Beyond clinical support, Protyon serves the life sciences industry by de-risking drug development pipelines through the assessment of mutation impact on protein behavior, drug resistance, and patient cohort selection for clinical trials. The company also provides medically accredited educational programs for clinicians to improve understanding of molecular drivers in disease, further supporting the integration of structural insights into oncology and precision medicine workflows.